According to a press release from Johnson & Johnson, a new study indicates that providing a booster dose of the Johnson & Johnson shot six months after first vaccination results in antibody levels 9-fold increase.
The findings might assist the US authorities to make recommendations concerning booster injections for the 14 million people who received the Johnson & Johnson single-shot vaccination.
Boosting after six months “appears to be safe” and “significantly increases immune responses,” according to Dr. Dan Barouch, Ph.D., head of Beth Israel Deaconess Medical Center’s Center for Virology and Vaccine Research.
In prepared remarks, Dr. Mathai Mammen, Global Head, Janssen Research & Development, Johnson & Johnson, stated that “a booster dose of the Johnson & Johnson COVID-19 vaccine significantly enhances antibody responses among study participants who had previously received our vaccine.”
According to scientists, new research shows that vaccination effectiveness for all three vaccines declines with time. Even if more frequent mild breakthrough infections have been recorded in the face of the highly transmissible delta variant, data suggests that vaccinations are still significantly decreasing the risk of hospitalization and death.
Nonetheless, given the current stage of the pandemic, federal health experts are more inclined to recommend booster doses.
“We are prepared to provide booster injections to all Americans beginning the week of September 20 and continuing for eight months following an individual’s second dose,” said CDC Director Rochelle Walensky during a press conference on Wednesday.
However, the Biden administration’s statement on booster dosages on Wednesday only applied to individuals who had Pfizer or Moderna injections, with no mention of those who received Johnson & Johnson. “With that data in hand, we will keep the public informed with a timely strategy for J&J booster injections as well,” Walensky said, adding that data on Johnson & Johnson may be anticipated “in the next few weeks.”
Vaccines from Pfizer and Moderna were approved in December 2020, while Johnson & Johnson received approval in February 2021. Because significant clinical studies for the Johnson & Johnson vaccine started months later than the other two, data for this vaccination is frequently disclosed a few weeks later.
The new information, which has just been presented in a press release and has not yet been peer-reviewed, will most likely be used to assist determine whether or not booster doses are required for people who received the Johnson & Johnson vaccine.
“It’s some of the data that people have been asking for and waiting for,” Barouch added.